Gastrointestinal diseases therapeutics market to grow by $18.5b in 2028

This is due to the rising prevalence of chronic digestive conditions.

The global gastrointestinal disease therapeutics market is estimated to grow by $18.5b from 2024 to 2028, with a compound annual growth rate of 6.81% according to Technavio. 

This is due to the rising prevalence of chronic digestive conditions like gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and gastrointestinal cancers.

Market trends include the use of telemedicine, biologics, Proton Pump Inhibitors (PPIs), aminosalicylates, antacids, laxatives, and H2 and H1 antagonists.

However, the high cost of gastrointestinal therapeutics may hinder market growth as the average treatment costs for ulcerative colitis and Crohn’s disease are $6,000 to $12,000 and $30,000 to $32,000, respectively. 

Market growth is expected in North America, Asia, Europe, and the rest of world.